Research programme: anticancer antibodies - GenetastixAlternative Names: Anti-CXCR4 antibody; Anti-IGF-r1 antibody
Latest Information Update: 18 Jan 2011
At a glance
- Originator Genetastix Corporation
- Class Antibodies
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 09 Jul 2004 Preclinical trials in Cancer in USA (unspecified route)